* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	APR 02	CAS Registry Number Crossover Limits Increased to 500,000 in Key STN Databases
NEWS 3	APR 02	PATDPAFULL: Application and priority number formats enhanced
NEWS 4	APR 02	DWPI: New display format ALLSTR available
NEWS 5	APR 02	New Thesaurus Added to Derwent Databases for Smooth Sailing through U.S. Patent Codes
NEWS 6	APR 02	EMBASE Adds Unique Records from MEDLINE, Expanding Coverage back to 1948
NEWS 7	APR 07	50,000 World Traditional Medicine (WTM) Patents Now Available in CAplus
NEWS 8	APR 07	MEDLINE Coverage Is Extended Back to 1947
NEWS 9	JUN 16	WPI First View (File WPIFV) will no longer be available after July 30, 2010
NEWS 10	JUN 18	DWPI: New coverage - French Granted Patents
NEWS 11	JUN 18	CAS and FIZ Karlsruhe announce plans for a new STN platform
NEWS 12	JUN 18	IPC codes have been added to the INSPEC backfile (1969-2009)
NEWS 13	JUN 21	Removal of Pre-IPC 8 data fields streamline displays in CA/CAplus, CASREACT,and MARPAT
NEWS 14	JUN 21	Access an additional 1.8 million records exclusively enhanced with 1.9 million CAS Registry Numbers -- EMBASE Classic on STN
NEWS 15	JUN 28	Introducing "CAS Chemistry Research Report": 40 Years of Biofuel Research Reveal China Now Atop U.S. in Patenting and Commercialization of Bioethanol
NEWS 16	JUN 29	Enhanced Batch Search Options in DGENE, USGENE, and PCTGEN
NEWS 17	JUL 19	Enhancement of citation information in INPADOC databases provides new, more efficient competitor analyses
NEWS 18	JUL 26	CAS coverage of global patent authorities has expanded to 61 with the addition of Costa Rica
NEWS 19	SEP 15	MEDLINE Cited References provide additional revelant records with no additional searching.
NEWS 20	OCT 04	Removal of Pre-IPC 8 data fields streamlines displays in USPATFULL, USPAT2, and USPATOLD.
NEWS 21	OCT 04	Precision of EMBASE searching enhanced with new chemical name field
NEWS 22	OCT 06	Increase your retrieval consistency with new formats or for Taiwanese application numbers in CA/CAplus.
NEWS 23	OCT 21	CA/CAplus kind code changes for Chinese patents increase consistency, save time
NEWS 24	OCT 22	New version of STN Viewer preserves custom highlighting of terms when patent documents are saved in .rtf format
NEWS 25	OCT 28	INPADOCDB/INPAFAMDB: Enhancements to the US national patent classification.
NEWS 26	NOV 03	New format for Korean patent application numbers in CA/CAplus increases consistency, saves time.
NEWS 27	NOV 04	Selected STN databases scheduled for removal on December 31, 2010
NEWS 28	NOV 18	PROUSDDR and SYNTHLINE Scheduled for Removal December 31, 2010 by Request of Prous Science
NEWS 29	NOV 22	Higher System Limits Increase the Power of STN Substance-Based Searching

```
 NEWS 30  NOV 22  Enjoy a free month of INPADOCDB/INPAFAMDB SDIs!
 NEWS 31  NOV 24  Search an additional 46,850 records with MEDLINE
                  backfile extension to 1946

 NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
          AND CURRENT DISCOVER FILE IS DATED 07 JULY 2010.

 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:34:01 ON 05 DEC 2010

=> file caplus biosis
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'CAPLUS' ENTERED AT 13:34:15 ON 05 DEC 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 13:34:15 ON 05 DEC 2010
Copyright (c) 2010 The Thomson Corporation

=> OX40 (L) antigen
L1          600 OX40 (L) ANTIGEN

=> HSV and L1
L2            5 HSV AND L1

=> D L2 IBIB ABS 1-5

L2   ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2010 ACS on STN
```

Full Text | Citing References

```
ACCESSION NUMBER:         2009:946400  CAPLUS
DOCUMENT NUMBER:          151:334437
TITLE:                    High Levels of Human Antigen-Specific CD4+ T Cells
                          in Peripheral Blood Revealed by Stimulated
                          Coexpression of CD25 and CD134 (OX40)
AUTHOR(S):                Zaunders, John J.; Munier, Mee Ling; Seddiki, Nabila;
                          Pett, Sarah; Ip, Susanna; Bailey, Michelle; Xu, Yin;
                          Brown, Kai; Dyer, Wayne B.; Kim, Min; de Rose, Robert;
                          Kent, Stephen J.; Jiang, Lele; Breit, Samuel N.;
                          Emery, Sean; Cunningham, Anthony L.; Cooper, David A.;
                          Kelleher, Anthony D.
CORPORATE SOURCE:         Centre for Immunology, St. Vincent's Hospital, Sydney,
```

Australia
SOURCE: Journal of Immunology (2009), 183(4), 2827-2836
CODEN: JOIMA3; ISSN: 0022-1767
PUBLISHER: American Association of Immunologists
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Ag-specific human CD4+ memory T lymphocytes have mostly been studied using assays of proliferation in vitro. Intracellular cytokine and ELISPOT assays quantify effector cell populations but barely detect responses to certain recall Ags that elicit strong proliferative responses, e.g., tetanus toxoid, that comprise non-Th1 CD4+ cells. The authors have found that culturing whole blood with Ag for 40-48 h induces specific CD4+ T cells to simultaneously express CD25 and CD134. This new technique readily detects responses to well-described CD4+ T cell recall Ags, including prepns. of mycobacteria, CMV, **HSV**-1, influenza, tetanus toxoid, Candida albicans, and streptokinase, as well as HIV-1 peptides, with high specificity. The assay detects much higher levels of Ag-specific cells than intracellular cytokine assays, plus the cells retain viability and can be sorted for in vitro expansion. Furthermore, current in vitro assays for human CD4+ memory T lymphocytes are too labor-intensive and difficult to standardize for routine diagnostic labs., whereas the whole-blood CD25+CD134+ assay combines simplicity of setup with a straightforward cell surface flow cytometry readout. In addn. to revealing the true extent of Ag-specific human CD4+ memory T lymphocytes, its greatest use will be as a simple in vitro monitor of CD4+ T cell responses to Ags such as tuberculosis infection or vaccines.
OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN
Full Text | Cited References

ACCESSION NUMBER: 2007:1091580 CAPLUS
DOCUMENT NUMBER: 148:353490
TITLE: Inhibition of OX40-Ig on herpetic stromal keratitis in murine model
AUTHOR(S): Xia, Likun; Chen, Xiaolong; Zhu, Yingming; Zhou, Jing
CORPORATE SOURCE: Department of Ophthalmology, Affiliated Second Hospital, China Medical University, Shenyang, 110004, Peop. Rep. China
SOURCE: Yanke Yanjiu (2006), 24(5), 479-483
CODEN: YAYAFH; ISSN: 1003-0808
PUBLISHER: Henan Institute of Ophthalmology
DOCUMENT TYPE: Journal
LANGUAGE: Chinese
AB Herpetic stromal keratitis (HSK) is an immunoinflammatory lesion in the cornea of the eye set off by the infection with **HSV**-1. The disease appears to be orchestrated by CD4+ T cells. In current study, it was investigated that the inhibition of OX40-Ig on the inhibition of HSK. Corneas of right eyes from 90 BALB/c mice were infected with 106 PFU of **HSV**-1 McKrae strain. Mice were injected i.p. with OX40-Ig or IgG Fc or PBS given on day 0, 2, 4 after the infection. CD4+ T cells from peripheral blood of mice were analyzed on FACS 440 analyzer. The clin. evaluations of infected eyes were taken under the slit-lamp microscope, and the histol. changes of corneas were obsd. under the optical microscope. Virus titers in corneas after **HSV**-1 infection were tested with VERO cells, and delayed type hypersensitivity was obsd. The effects of OX40-Ig on HSK were evaluated. As measured by flow cytometry, in the

mice treated with OX40-Ig, 78.2% of CD4+ T cells were reduced. 83.3% Of the **HSV**-1-infected control mice developed severe stromal keratitis, but only 20.0% of mice treated by OX40-Ig developed HSK. Lesions in OX40-Ig treated mice showed markedly reduced severity by slit-lamp microscope, and histol. the corneal stroma had a decrease in inflammatory cell infiltration compared to the control group, and the delayed type hypersensitivity was reduced. The results provide an evidence that blockade of OX-40/OX-40L co-stimulation by OX40-Ig can inhibit the proliferation of CD4+ T cells and impair onset and severity of HSK.

L2 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2007:254551 CAPLUS
DOCUMENT NUMBER: 146:294007
TITLE: Expression and function of the OX40/OX40L costimulatory pair during herpes stromal keratitis
AUTHOR(S): Lepisto, Andrew J.; Xu, Min; Yagita, Hideo; Weinberg, Andrew D.; Hendricks, Robert L.
CORPORATE SOURCE: Department of Ophthalmology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
SOURCE: Journal of Leukocyte Biology (2006), Volume Date 2007, 81(3), 766-774
CODEN: JLBIE7; ISSN: 0741-5400
PUBLISHER: Federation of American Societies for Experimental Biology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Herpes stromal keratitis (HSK) is an immunopathol. disease regulated by Th1 CD4 T cells, which require APC and costimulation within the infected cornea to mediate disease. Recent studies suggest the OX40:OX40 ligand (OX40L) interaction enhances effector cell cytokine secretion at inflammatory sites. OX40+ cells were detected in **HSV**-1-infected mouse corneas as early as 3 days postinfection (dpi), prior to the onset of HSK, and their frequency increased through 15 dpi, when all mice exhibited severe HSK. OX40L+ cells were first detected at 7 dpi, coincident with the initiation of HSK. It is interesting that the OX40L+ cells did not coexpress MHC class II or the dendritic cell (DC) marker CD11c. The authors' findings demonstrate rapid infiltration of activated (OX40+) CD4+ T cells into **HSV**-1-infected corneas and expression of OX40L on MHC class II-neg. cells but surprisingly, not on MHC class II+ CD11c+ DC, which are present in the infected corneas and required for HSK. Moreover, neither local nor systemic treatment of mice with a blocking antibody to OX40L or with a blocking fusion protein altered the course of HSK, possibly as a result of a lack of OX40L expression on functional APC.

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2004:679028 CAPLUS
DOCUMENT NUMBER: 141:409506
TITLE: Anti-tumor therapeutic efficacy of OX40L in murine tumor model
AUTHOR(S): Ali, Selman A.; Ahmad, Murrium; Lynam, June; McLean, Cornelia S.; Entwisle, Claire; Loudon, Peter; Choolun, Esther; McArdle, Stephanie E. B.; Li, Geng; Mian,

Shahid; Rees, Robert C.
CORPORATE SOURCE: School of Science, Nottingham Trent University, Nottingham, NG11 8NS, UK
SOURCE: Vaccine (2004), 22(27-28), 3585-3594
CODEN: VACCDE; ISSN: 0264-410X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB **OX40** ligand (OX40L), a member of TNF superfamily, is a co-stimulatory mol. involved in T cell activation. Systemic administration of mOX40L fusion protein significantly inhibited the growth of exptl. lung metastasis and s.c. established colon (CT26) and breast (4T1) carcinomas. Vaccination with OX40L was significantly enhanced by combination treatment with intra-tumor injection of a disabled infectious single cycle-herpes simplex virus (DISC-**HSV**) vector encoding murine granulocyte macrophage-colony stimulating factor (mGM-CSF). Tumor rejection in response to OX40L therapy required functional CD4+ and CD8+ T cells and correlated with splenocyte cytotoxic T lymphocytes (CTLs) activity against the AH-1 gp70 peptide of the tumor assocd. **antigen** expressed by CT26 cells. These results demonstrate the potential role of the OX40L in cancer immunotherapy.
OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)
REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 5 OF 5 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN

Full Text | Info. Reference

ACCESSION NUMBER: 2004:452715 BIOSIS
DOCUMENT NUMBER: PREV200400449410
TITLE: Anti-tumour therapeutic efficacy of OX40L in murine tumour model.
AUTHOR(S): Ali, Selman A.; Ahmad, Murrium; Lynam, June; McLean, Cornelia S.; Entwisle, Claire; Loudon, Peter; Choolun, Esther; McArdle, Stephanie E. B.; Li, Geng; Mian, Shahid; Rees, Robert C. [Reprint Author]
CORPORATE SOURCE: Sch Sci, Nottingham Trent Univ, Clifton Lane, Nottingham, NG11 8NS, UK
robert.rees@ntu.ac.uk
SOURCE: Vaccine, (September 9 2004) Vol. 22, No. 27-28, pp. 3585-3594. print.
ISSN: 0264-410X (ISSN print).
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 24 Nov 2004
Last Updated on STN: 24 Nov 2004
AB **OX40** ligand (OX40L), a member of TNF superfamily, is a co-stimulatory molecule involved in T cell activation. Systemic administration of mOX40L fusion protein significantly inhibited the growth of experimental lung metastasis and subcutaneous (s.c.) established colon (CT26) and breast (4T1) carcinomas. Vaccination with OX40L was significantly enhanced by combination treatment with intra-tumour injection of a disabled infectious single cycle-herpes simplex virus (DISC-**HSV**) vector encoding murine granulocyte macrophage-colony stimulating factor (mGM-CSF). Tumour rejection in response to OX40L therapy required functional CD4+ and CD8+ T cells and correlated with splenocyte cytotoxic T lymphocytes (CTLs) activity against the AH-1 gp70 peptide of the tumour associated **antigen** expressed by CT26 cells. These results demonstrate the potential role of the OX40L in cancer immunotherapy. Copyright 2004 Elsevier Ltd. All

rights reserved.

=> DNA vaccine and l1
L3 4 DNA VACCINE AND L1

=> D L3 IBIB ABS 1-4

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN
Full Text | Citing References

ACCESSION NUMBER: 2007:859817 CAPLUS
DOCUMENT NUMBER: 147:298670
TITLE: Enhanced protective efficacy and reduced viral load of foot-and-mouth disease **DNA vaccine** with co-stimulatory molecules as the molecular adjuvants
AUTHOR(S): Xiao, Chong; Jin, Huali; Hu, Yanxin; Kang, Youmin; Wang, Junpeng; Du, Xiaogang; Yang, Yu; She, Ruiping; Wang, Bin
CORPORATE SOURCE: State Key Laboratory for Agro-Biotechnology, Key Laboratory of Agro-Microbial Resources and Applications of MOA, China Agricultural University, Beijing, 100094, Peop. Rep. China
SOURCE: Antiviral Research (2007), 76(1), 11-20
CODEN: ARSRDR; ISSN: 0166-3542
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB To improve efficacy of DNA vaccination, various approaches have been developed, including the use of plasmid expressing co-stimulatory mols. as mol. adjuvants. Here, the authors investigated whether co-inoculation of a construct expressing either 4-1BBL or OX40L as the mol. adjuvant with FMDV **DNA vaccine**, pcD-VP1, can increase immune responses and protective efficacies. Compared to the group immunized with pcD-VP1 alone, the co-inoculation of either mol. adjuvant induced a higher ratio of IgG2a/IgG1, higher levels of expression of IFN-γ in CD4+ and CD8+ T cells and antigen-specific CTL responses, and more importantly provided an enhanced protection against the live FMDV challenge in animals. Concurrently, 4-1BBL as the mol. adjuvant dramatically reduced the viral loads of FMDV in vivo after the challenge. Thus, co-stimulatory mols. 4-1BBL and OX40L can enhance the antigen-specific cell-mediated responses elicited by VP1 **DNA vaccine** and provide an enhanced protective efficacy with the reduced viral loads.
OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN
Full Text | Citing References

ACCESSION NUMBER: 2004:1156439 CAPLUS
DOCUMENT NUMBER: 142:73408
TITLE: **DNA vaccines** comprising immunomodulatory proteins and antigen from pathogens
INVENTOR(S): Weiner, David B.; Muthumani, Karuppiah; Kutzler, Michele; Choo, Andrew K.; Chattergoon, Michael A.
PATENT ASSIGNEE(S): The Trustees of the University of Pennsylvania, USA
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004112706	A2	20041229	WO 2004-US19028		20040614
WO 2004112706	A3	20050414			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004249191	A1	20041229	AU 2004-249191		20040614
CA 2529051	A1	20041229	CA 2004-2529051		20040614
EP 1633372	A2	20060315	EP 2004-755303		20040614
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
JP 2007502868	T	20070215	JP 2006-533794		20040614
US 20070104686	A1	20070510	US 2004-560653		20040614
PRIORITY APPLN. INFO.:			US 2003-478187P	P	20030613
			US 2003-478230P	P	20030613
			US 2003-478250P	P	20030613
			WO 2004-US19028	W	20040614

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The authors disclose the use of recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid mols. that encode an immunogen in combination with an isolated nucleic acid mol. that encodes an immunomodulator protein selected from the group consisting of: Fos, c-jun, Sp-1, AP-1, AP-2, p38, p65Rel, MyD88, IRAK, TRAF6, IκB, inactive NIK, SAP kinase, SAP-1, JNK, interferon response genes, NF-κB, Bax, TRAIL, TRAIL receptors, DcR5, TRAIL-R3, TRAIL-R4, RANK, RANK ligand, Ox40, Ox40 ligand, NKG2D, MICA, MICB, NKG2A, NKG2B, NKG2C, NKG2E, NKG2F, TAP1, TAP2 and functional fragments thereof.

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2001:313168 CAPLUS
TITLE: Papers to Appear in Forthcoming Issues
AUTHOR(S): Anon
SOURCE: Cellular Immunology (2001), 208(2), 148
CODEN: CLIMB8; ISSN: 0008-8749
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB (Received and Accepted Dates Follow Title)Mice Disrupted for the KvLQT1 Potassium Channel Regulator IsK Gene Accumulate Mature T Cells. Dominique Chabannes, Jacques Barhanin, and Denis Escande. (Received 9/27/00;

accepted 3/7/01.)Pos. and Neg. Consequences of Sol. Fas Ligand Produced by an **Antigen**-Specific CD4+ T Cell Response in Human Carcinoma Immune Interactions. Elke S. Bergmann-Leitner and Scott I. Abrams. (Received 12/18/00; accepted 3/7/01.)Mol. Cloning and Expression Pattern of Porcine Myeloid DAP12-Assocg. Lectin-1. Daesong Yim, Hyun-Bae Jie, John Sotiriadis, Yoon-Sang Kim, and Yoon B. Kim. (Received 12/13/00; accepted 3/4/01.)**OX40** Ligation Enhances Cell Cycle Turnover of Ag-Activated CD4 T Cells in Vivo. Amy R. Weatherill, Joseph R. Maxwell, Chikara Takahashi, Andrew D. Weinberg, and Anthony T. Vella. (Received 1/23/01; accepted 3/10/01.)Codelivery of DNA Coding for the Sol. Form of CD86 Results in the Down-Regulation of the Immune Response to **DNA Vaccines**. Juan Flo, Sergio Tisminetzky, and Francisco Baralle. (Received 10/23/00; accepted 3/18/01.)Dendritic Cells Issued in Vitro from Bone Marrow Produce PGE2 That Contributes to the Immunomodulation Induced by **Antigen**-Presenting Cells. H. Harizi, M. Juzan, C. Grosset, M. Rashedi, and N. Gualde. (Received 11/24/00; accepted 3/15/01.)A "Chimeric" C57L-Derived Ly49 Inhibitory Receptor Resembling the Ly49D Activation Receptor. Indira K. Mehta, Hamish R. C. Smith, Jian Wang, David H. Margulies, and Wayne M. Yokoyama. (Received 1/17/01; accepted 3/14/01.)Idiotypic-Anti-idiotypic B Cell Interactions Generated against a Protective **Antigen** of a Morbillivirus in Mice. Shibani Mitra-Kaushik, M. S. Shaila, Anjali Karanade, and Rabindranath Nayak. (Received 10/16/00; accepted 3/22/01.). (c) 2001 Academic Press.

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN

Full Text | Cited References

ACCESSION NUMBER: 1998:684978 CAPLUS
DOCUMENT NUMBER: 129:274700
ORIGINAL REFERENCE NO.: 129:56017a,56020a
TITLE: DNA encoding targeting protein fused to antigen or epitope in enhancement of immune response to **DNA vaccines**
INVENTOR(S): Boyle, Jefferey Stephen; Brady, Jamie Louise; Lew, Andrew Mark
PATENT ASSIGNEE(S): The Council of the Queensland Institute of Medical Research, Australia; Commonwealth Scientific and Industrial Research Organisation; The University of Melbourne; The Walter and Eliza Hall Institute of Medical Research; CSL Ltd.
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9844129	A1	19981008	WO 1998-AU208	19980326
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2285692	A1	19981008	CA 1998-2285692	19980326
AU 9864902	A	19981022	AU 1998-64902	19980326

AU 728962	B2	20010125			
EP 972054	A1	20000119	EP 1998-910530		19980326
EP 972054	B1	20081210			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
NZ 500151	A	20010126	NZ 1998-500151		19980326
JP 2001522235	T	20011113	JP 1998-540989		19980326
JP 4382163	B2	20091209			
AT 417112	T	20081215	AT 1998-910530		19980326
ZA 9802608	A	19981008	ZA 1998-2608		19980327
US 20030035793	A1	20030220	US 2002-185318		20020628
US 7423016	B2	20080909			
US 20030072742	A1	20030417	US 2002-185799		20020628
US 7423023	B2	20080909			
CA 2489940	A1	20060608	CA 2004-2489940		20041208
PRIORITY APPLN. INFO.:			AU 1997-5891	A	19970327
			AU 1998-1830	A	19980213
			WO 1998-AU208	W	19980326
			US 2000-402020	A1	20000328

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention provides methods of enhancing the immune response to an immunogen and to compns. for use in these methods. In particular the present invention provides a DNA mol. for use in raising an immune response to an antigen. The DNA mol. includes a first sequence encoding a targeting mol., a second sequence encoding the antigen or an epitope thereof, and optionally a third sequence encoding a polypeptide which promotes dimerization or multimerization of the product encoded by the DNA mol. Immunization of mice with a no. of DNA sequences encoding CTLA4-antigen fusions enhanced the immune response to the antigen.

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>